Rubraca Shrank Tumors in Nearly Half of Advanced Prostate Cancer Patients with BRCA Mutations

Rubraca Shrank Tumors in Nearly Half of Advanced Prostate Cancer Patients with BRCA Mutations
Rubraca (rucaparib), Clovis Oncology's PARP inhibitor, shrank tumors in 44% of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations included in a Phase 2 clinical trial, the company announced. The treatment, which already is approved for ovarian cancer, also reduced PSA levels — a biomarker of prostate cancer — in 51.1% of patients with BRCA mutations. The findings were presented recently at the European Society of Medical Oncology (ESMO) 2018 Congress by Wassim Abida, a medical oncologist at the Memorial Sloan Kettering Cancer Center, and principal investi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *